Current and potential treatment options for invasive Candida infections

References

• Huffnagle GB, Noverr MC. The emerging world of the fungal microbiome. Trends Microbiol. 2013 Jul;21(7):334–341.
   Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 Jun 15;46(12):1813–1821.
   Google Scholar
• Brown GD, Denning DW, Gow NAR, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.
   Google Scholar
• Tan BH, Chakrabarti A, Li RY, et al. Incidence and species distribution of candidaemia in asia: a laboratory-based surveillance study. Clin Microbiol Infect. 2015 Oct;21(10):946–953.
   Google Scholar
• Vallabhaneni S, Mody RK, Walker T, et al. The global burden of fungal diseases. Infect Dis Clin North Am. 2016 Mar;30(1):1–11.
   Google Scholar
• Dignani MC. Epidemiology of invasive fungal diseases on the basis of autopsy reports. F1000prime Reports. 2014;6:81.
   Google Scholar
• Strollo S, Lionakis MS, Adjemian J, et al. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002-2012. Emerg Infect Dis. 2016 Jan;23(1):7–13.
   Google Scholar
• Ben R, Denning DW. Estimating the burden of fungal diseases in Israel. Isr Med Assoc Journal: IMAJ. 2015 Jun;17(6):374–379.
   Google Scholar
• Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 2014 Jul;20(7):1149–1155.
   Google Scholar
• Marzaban R, Salah M, Mukhtar AM, et al. Fungal infections in liver transplant patients admitted to the intensive care unit. Ann Transplantation. 2014 Dec 22;19:667–673.
   Google Scholar
• Arendrup MC. Candida and candidaemia. Susceptibility and epidemiology. Dan Med J. 2013 Nov;60(11):B4698.
   Google Scholar
• Eliakim-Raz N, Babaoff R, Yahav D, et al. Epidemiology, microbiology, clinical characteristics, and outcomes of candidemia in internal medicine wards-a retrospective study. Int J Infect Dis. 2016;52:49–54.
   Google Scholar
• Timsit JF, Perner A, Bakker J, et al. Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med. 2015 Apr;41(4):575–588.
   Google Scholar
• Caggiano G, Coretti C, Bartolomeo N, et al. Candida bloodstream infections in Italy: changing epidemiology during 16 years of surveillance. Biomed Res Int. 2015;2015:256580.
   Google Scholar
• Kim GY, Jeon JS, Kim JK. Isolation frequency characteristics of Candida species from clinical specimens. Mycobiology. 2016 Jun;44(2):99–104.
   Google Scholar
• Baldesi O, Bailly S, Ruckly S, et al. REA-RAISIN network. ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004-2013 - a study from the REA-RAISIN network. J Infect. 2017 Jul;75(1):59–67.
   Google Scholar
• Bassetti M, Peghin M, Carnelutti A, et al. Invasive Candida infections in liver transplant recipients: clinical features and risk factors for mortality. Transplant Direct. 2017 Apr 18;3(5):e156.
   Google Scholar
• Bassetti M, Peghin M, Timsit JF. The current treatment landscape: candidiasis. J Antimicrob Chemother. 2016 Nov;71(suppl 2):ii13–ii22.
   Google Scholar
• Lockhart SR, Wagner D, Iqbal N, et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol. 2011 Jul;49(7):2404–2410.
   Google Scholar
• Bassetti M, Garnacho-Montero J, Calandra T, et al. Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med. 2017 Mar 2;43:1225–1238.
   Google Scholar
• Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the prospective antifungal therapy (path) registry 2004-2008. PloS One. 2014;9(7):e101510.
   Google Scholar
• Jung SI, Shin JH, Song JH, et al. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycology. 2010 Jun;48(4):669–674.
   Google Scholar
• Tedeschi S, Tumietto F, Giannella M, et al. Epidemiology and outcome of candidemia in internal medicine wards: a regional study in Italy. Eur J Intern Med. 2016;34:39–44.
   Google Scholar
• Pongracz J, Juhasz E, Ivan M, et al. Significance of yeasts in bloodstream infection: epidemiology and predisposing factors of candidaemia in adult patients at a university hospital (2010-2014). Acta Microbiol Immunol Hung. 2015 Sep;62(3):317–329.
   Google Scholar
• Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014 Jun;20(Suppl 6):5–10.
   Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the artemis disk global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010 Apr;48(4):1366–1377.
   Google Scholar
• Nieto MC, Tellería O, Cisterna R. Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility. Diagn Microbiol Infect Dis. 2015 Jan;81(1):34–40.
   Google Scholar
• Pratikaki M, Platsouka E, Sotiropoulou C, et al. Epidemiology, risk factors for and outcome of candidaemia among non-neutropenic patients in a Greek intensive care unit. Mycoses. 2011 Mar;54(2):154–161.
   Google Scholar
• Figueiredo-Carvalho MH, Ramos Lde S, Barbedo LS, et al. First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes. Memorias Do Instituto Oswaldo Cruz. 2016 Jan;111(1):51–58.
   Google Scholar
• Chowdhary A, Voss A, Meis JF. Multidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections? J Hosp Infect. 2016 Nov;94(3):209–212.
   Google Scholar
• Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008 Nov;32(Suppl 2):S87–S91.
   Google Scholar
• Bassetti M, Molinari MP, Mussap M, et al. Candidaemia in internal medicine departments: the burden of a rising problem. Clin Microbiol Infect. 2013 Jun;19(6):E281–E284.
   Google Scholar
• Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med. 2014 Oct;40(10):1429–1448.
   Google Scholar
• Lagunes L, Rello J. Invasive candidiasis: from mycobiome to infection, therapy, and prevention. Eur J Clin Microbiol Infect Dis. 2016 Aug;35(8):1221–1226.
   Google Scholar
• Forster TM, Mogavero S, Drager A, et al. Enemies and brothers in arms: Candida albicans and gram-positive bacteria. Cell Microbiol. 2016 Dec;18(12):1709–1715.
   Google Scholar
• Seneviratne CJ, Rajan S, Wong SS, et al. Antifungal susceptibility in serum and virulence determinants of Candida bloodstream isolates from Hong Kong. Front Microbiol. 2016;7:216.
   Google Scholar
• van de Veerdonk FL, Joosten LA, Netea MG. The interplay between inflammasome activation and antifungal host defense. Immunol Rev. 2015 May;265(1):172–180.
   Google Scholar
• Steinbach WJ, Roilides E, Berman D, et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012 Dec;31(12):1252–1257.
   Google Scholar
• Karadag-Oncel E 1, Kara A, Ozsurekci Y, et al. Candidaemia in a paediatric centre and importance of central venous catheter removal. Mycoses. 2015 Mar;58(3):140–148.
   Google Scholar
• Dutcher JD. The discovery and development of amphotericin B. Dis Chest. 1968 Oct;54(Suppl 1):296–298.
   Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011 Aug;86(8):805–817.
   Google Scholar
• Kaminski DM. Recent progress in the study of the interactions of amphotericin b with cholesterol and ergosterol in lipid environments. Eur Biophys J. 2014 Nov;43(10–11):453–467.
   Google Scholar
• Sud IJ, Feingold DS. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol. 1981 Jun;76(6):438–441.
   Google Scholar
• Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect. 2004 Mar;10(Suppl 1):1–10.
   Google Scholar
• Heeres J, Meerpoel L, Lewi P. Conazoles. Molecules. 2010 Jun 09;15(6):4129–4188.
   Google Scholar
• Bodey GP. Azole antifungal agents. Clin Infect Dis. 1992 Mar;14(Suppl 1):S161–S169.
   Google Scholar
• Lass-Florl C. Triazole antifungal agents in invasive fungal infections: a comparative review. Drugs. 2011 Dec 24;71(18):2405–2419.
   Google Scholar
• Jensen RH, Johansen HK, Soes LM, et al. Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1500–1508.
   Google Scholar
• Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002 Mar 30;359(9312):1135–1144.
   Google Scholar
• Dewan E, Biswas D, Kakati B, et al. Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in india. Hematol Oncol Stem Cell Ther. 2015 Sep;8(3):99–105.
   Google Scholar
• Calvo B, Melo AS, Perozo-Mena A, et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016 Oct;73(4):369–374.
   Google Scholar
• Mesa-Arango AC, Rueda C, Roman E, et al. Cell wall changes in amphotericin b-resistant strains from Candida tropicalis and relationship with the immune responses elicited by the host. Antimicrob Agents Chemother. 2016 Apr;60(4):2326–2335.
   Google Scholar
• Asner SA, Giulieri S, Diezi M, et al. Acquired multidrug antifungal resistance in Candida lusitaniae during therapy. Antimicrob Agents Chemother. 2015 Dec;59(12):7715–7722.
   Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003 May 1;36(9):1122–1131.
   Google Scholar
• Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother. 2008 Oct;42(10):1429–1438.
   Google Scholar
• Girmenia C, Iori AP. Safety and interactions of new antifungals in stem cell transplant recipients. Expert Opin Drug Saf. 2012 Sep;11(5):803–818.
   Google Scholar
• Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther. 2009 Oct;7(8):981–998.
   Google Scholar
• Ruhnke M, Hartwig K, Kofla G. New options for treatment of candidaemia in critically ill patients. Clin Microbiol Infect. 2008 May;14(Suppl 4):46–54.
   Google Scholar
• Ullmann AJ, Akova M, Herbrecht R, et al. Escmid* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012 Dec;18(Suppl 7):53–67.
   Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1–e50.
   Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017 Mar;102(3):433–444.
   Google Scholar
• Uzun O, Anaissie EJ. Problems and controversies in the management of hematogenous candidiasis. Clin Infect Dis. 1996 May;22(Suppl 2):S95–S101.
   Google Scholar
• Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009 May;37(5):1612–1618.
   Google Scholar
• Aguilar G, Delgado C, Corrales I, et al. Epidemiology of invasive candidiasis in a surgical intensive care unit: an observational study. BMC Res Notes. 2015 Sep;29(8):491.
   Google Scholar
• Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol. 2010 Jul;48(7):2373–2380.
   Google Scholar
• Hou TY, Wang SH, Liang SX, et al. The screening performance of serum 1,3-beta-d-glucan in patients with invasive fungal diseases: a meta-analysis of prospective cohort studies. PloS One. 2015;10(7):e0131602.
   Google Scholar
• Martinez-Jimenez MC, Munoz P, Valerio M, et al. Candida biomarkers in patients with candidaemia and bacteraemia. J Antimicrob Chemother. 2015 Aug;70(8):2354–2361.
   Google Scholar
• Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15;60(6):892–899.
   Google Scholar
• Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017 Jul 12.
   Google Scholar
• Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009 May 15;48(10):1441–1458.
   Google Scholar
• Dolton MJ, Bruggemann RJ, Burger DM, et al. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Antimicrob Agents Chemother. 2014 Nov;58(11):6879–6885.
   Google Scholar
• Liu P, Mould DR. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis. Antimicrob Agents Chemother. 2014 Aug;58(8):4718–4726.
   Google Scholar
• Malani AN, Kerr LE, Kauffman CA. Voriconazole: how to use this antifungal agent and what to expect. Semin Respir Crit Care Med. 2015 Oct;36(5):786–795.
   Google Scholar
• Neofytos D, Ostrander D, Shoham S, et al. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial. Transpl Infect Dis. 2015 Dec;17(6):831–837.
   Google Scholar
• Cabral-Galeano E, Ruiz-Camps I, Len-Abad O, et al. Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital. Enferm Infecc Microbiol Clin. 2015 May;33(5):298–302.
   Google Scholar
• Lempers VJ, Martial LC, Schreuder MF, et al. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Curr Opin Pharmacol. 2015 Oct;24:38–44.
   Google Scholar
• Murat JB, Lebeau B, Chumpitazi B, et al. Minimum inhibitory concentrations of amphotericin b against Candida krusei isolates from a french teaching hospital laboratory: a retrospective study over 8 years. Mycoses. 2013 Jan;56(1):56–60.
   Google Scholar
• Messer SA, Jones RN, Moet GJ, et al. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global sentry antimicrobial surveillance program (2008). J Clin Microbiol. 2010 Aug;48(8):2984–2987.
   Google Scholar
• Bailly S, Maubon D, Fournier P, et al. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. - trends over 10 years. J Infect. 2016 Jan;72(1):103–111.
   Google Scholar
• Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol. 2003 Jan;41(1):78–83.
   Google Scholar
• Perlin DS. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs. 2014 Sep;74(14):1573–1585.
   Google Scholar
• Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013 Oct;22(6):163–174.
   Google Scholar
• Seyedmousavi S, Verweij PE, Mouton JW. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. Expert Rev Anti Infect Ther. 2015 Jan;13(1):9–27.
   Google Scholar
• Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug bal8557. Antimicrob Agents Chemother. 2009 Nov;53(11):4885–4890.
   Google Scholar
• Cornely OA, Bohme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015 Apr;59(4):2078–2085.
   Google Scholar
• Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (bal4815), voriconazole, and fluconazole against 1,007 isolates of Zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother. 2008 Apr;52(4):1396–1400.
   Google Scholar
• Viljoen J, Azie N, Schmitt-Hoffmann AH, et al. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis. Antimicrob Agents Chemother. 2015 Mar;59(3):1671–1679.
   Google Scholar
• McCormack PL. Isavuconazonium: first global approval. Drugs. 2015 May;75(7):817–822.
   Google Scholar
• Thompson G, Alangaden G, Santos R, et al. A phase III, double-blind, randomized study to evaluate the safety and efficacy of BAL8557 versus caspofungin followed by voriconazole in the treatment of candidemia and other invasive Candida infections (abstract). 26th European Conference on Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases, Amsterdam Netherlands, 2016.
   Google Scholar
• Sanglard D, Coste AT. Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms. Antimicrob Agents Chemother. 2015 Oct 19;60(1):229–238.
   Google Scholar
• Kathuria S, Singh PK, Sharma C, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by vitek 2, clsi broth microdilution, and etest method. J Clin Microbiol. 2015 Jun;53(6):1823–1830.
   Google Scholar
• Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-d-glucan synthase inhibitors. Antimicrob Agents Chemother. 2000 Feb;44(2):368–377.
   Google Scholar
• Pfaller MA, Messer SA, Motyl MR, et al. Activity of mk-3118, a new oral glucan synthase inhibitor, tested against candida spp. By two international methods (CLSI and EUCAST). J Antimicrob Chemother. 2013 Apr;68(4):858–863.
   Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida species. Antimicrob Agents Chemother. 2017 May 22;61:e00161-17.
   Google Scholar
• Marcos-Zambrano LJ, Gómez-Perosanz M, Escribano P, et al. The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp. J Antimicrob Chemother. 2017 Apr 26;72:1969–1976. [Epub ahead of print].
   Google Scholar
• James KD, Laudeman CP, Malkar NB, et al. Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties. Antimicrob Agents Chemother. 2017 Jan 24;61(2):pii: e01541-16.
   Google Scholar
• Ong V, Hough G, Schlosser M, et al. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6872–6879.
   Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. J Antimicrob Chemother. 2016 Oct;71(10):2868–2873.
   Google Scholar
• Sandison T, Ong V, Lee J, et al. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017 Jan 24;61(2):pii: e01627-16.
   Google Scholar
• Hagiya H, Kajioka H. Successful treatment of recurrent candidemia due to candidal thrombophlebitis associated with a central venous catheter using a combination of fosfluconazole and micafungin. Intern Med. 2013;52(18):2139–2143.
   Google Scholar
• Bland CM, Thomas S. Micafungin plus fluconazole in an infected knee with retained hardware due to Candida albicans. Ann Pharmacother. 2009 Mar;43(3):528–531.
   Google Scholar
• Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence. 2016 Jun;07:1–17.
   Google Scholar